>
Fa   |   Ar   |   En
   evaluation of weight based enoxaparin dosing on anti-xa concentrations in patients with obesity  
   
نویسنده oosterom nameer van ,winckel karl ,barras michael
منبع journal of thrombosis and thrombolysis - 2019 - دوره : 48 - شماره : 3 - صفحه:387 -393
چکیده    Current treatment dose of enoxaparin is based on total body weight (tbw), however dosage in obesity remains unclear. “dose capping” commonly occurs if tbw > 100 kg minimising bleeding risk. however, this result in under-dosing and increasing embolisation risk. the primary objective evaluated efficacy of current dosing strategies in obese patients and determined if resultant anti-xa concentrations (axac) were therapeutic. the secondary objective was to investigate if an uncapped 0.75–0.85 mg/kg (tbw) twice daily dose, advocated by previous authors, results in therapeutic axac (0.5–1.0 iu/ml). this retrospective study included 133 patients with a median tbw of 128 kg, producing 59% therapeutic, 15% sub-therapeutic and 26% supra-therapeutic axac. approximately 60% of patients in each dose group (< 0.75, 0.75–0.85 and > 0.85 mg/kg) had a therapeutic axac, however the percentage of sub-therapeutic versus supra-therapeutic was higher in the < 0.75 (27% vs 9%) and > 0.85 mg/kg (10% vs 34%) groups respectively. most patients who weighed 100–119 kg (tbw) received doses > 0.85 mg/kg, however 32% had toxic axac. those between 120 and 139 kg (tbw) had a high percentage of therapeutic axac (87%) when dosed < 0.75 mg/kg and a high percentage of supra-therapeutic axac (71%) when dosed > 0.85 mg/kg; although numbers were low. dose reduction occurred in patients > 140 kg (tbw), however < 0.75 mg/kg resulted in higher percentage of sub-therapeutic axac (42%). dosing at 0.75–0.85 mg/kg results in 62% of therapeutic, 14% sub-therapeutic and 24% supra-therapeutic axac. this appears to be a “safe” starting dose-range, however all obese patients should have axac monitoring due to high inter-patient variability.
کلیدواژه enoxaparin ,low-molecular weight heparin ,obesity ,morbid obesity ,anticoagulation ,anti-xa
آدرس princess alexandra hospital, australia. university of queensland, australia, princess alexandra hospital, australia. university of queensland, australia, princess alexandra hospital, australia. university of queensland, australia
 
     
   
Authors
  
 
 

Copyright 2023
Islamic World Science Citation Center
All Rights Reserved